Cargando…

Safety, feasibility, and hemodynamic response of regadenoson for stress perfusion CMR

Owing to its pharmacodynamics and posology, the use of regadenoson for stress cardiac magnetic resonance (CMR) has potential advantages over other vasodilators. We sought to evaluate the safety, hemodynamic response and diagnostic performance of regadenoson stress-CMR in routine clinical practice. A...

Descripción completa

Detalles Bibliográficos
Autores principales: Muñiz-Sáenz-Diez, Javier, Ezponda, Ana, Caballeros, Meylin, de la Fuente, Ana, Gavira, Juan J., Bastarrika, Gorka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10520095/
https://www.ncbi.nlm.nih.gov/pubmed/37354385
http://dx.doi.org/10.1007/s10554-023-02877-z
_version_ 1785109838500462592
author Muñiz-Sáenz-Diez, Javier
Ezponda, Ana
Caballeros, Meylin
de la Fuente, Ana
Gavira, Juan J.
Bastarrika, Gorka
author_facet Muñiz-Sáenz-Diez, Javier
Ezponda, Ana
Caballeros, Meylin
de la Fuente, Ana
Gavira, Juan J.
Bastarrika, Gorka
author_sort Muñiz-Sáenz-Diez, Javier
collection PubMed
description Owing to its pharmacodynamics and posology, the use of regadenoson for stress cardiac magnetic resonance (CMR) has potential advantages over other vasodilators. We sought to evaluate the safety, hemodynamic response and diagnostic performance of regadenoson stress-CMR in routine clinical practice. All regadenoson stress-CMR examinations performed between May 2017 and July 2020 at our institution were retrospectively reviewed. A total of 698 studies were included for the final analysis. A conventional stress/rest protocol was performed using a 1.5T MRI scanner (Magnetom Aera, Siemens Healthineers, Erlangen, Germany). Adverse events, clinical symptoms, and hemodynamic response were assessed. Diagnostic accuracy of the test was evaluated in patients who underwent invasive coronary angiography. Nearly half of patients (48.5%) remained asymptomatic. Most common clinical symptoms included dyspnea (137, 19.6%), chest pain (116, 16.6%) and flushing (44, 6.3%). Two patients (0.28%) could not complete the examination due to severe hypotension or unbearable chest pain. Overall, an increase in heart rate (HR) response (36.2% [IQR: 22.5?50.9]) and a decrease in systolic and diastolic blood pressure (BP) (median systolic BP response of -5% [IQR: -11.5-0.6]; median diastolic BP response of -6.3 mmHg [IQR: -13.4-0]) was observed. Patients with symptoms induced by regadenoson showed higher HR response (40.3%, IQR: 26.4?56.1 vs. 32.4%, IQR: 19-45.6, p < 0.001), whereas a blunted HR response was observed in diabetic (29.6%, IQR: 18.4?42 p < 0.001), obese (31.7%, IQR: 20.7?46.2 p = 0.005) and patients aged 70 years or older (32.9%, IQR: 22.6?43.1 p < 0.001). Overall, regadenoson stress-CMR showed 95.65% (IQ 91.49?99.81) sensitivity, 54.84% (IQ 35.71?73.97) specificity, 86.99% (IQ 82.74?94.68) positive predictive value, and 77.27% (IQ 57.49?97.06) negative predictive value for detecting significant coronary stenosis as compared with invasive coronary angiography. Regadenoson is a well-tolerated vasodilator that can be safely employed for stress perfusion CMR, with high diagnostic performance.
format Online
Article
Text
id pubmed-10520095
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Netherlands
record_format MEDLINE/PubMed
spelling pubmed-105200952023-09-27 Safety, feasibility, and hemodynamic response of regadenoson for stress perfusion CMR Muñiz-Sáenz-Diez, Javier Ezponda, Ana Caballeros, Meylin de la Fuente, Ana Gavira, Juan J. Bastarrika, Gorka Int J Cardiovasc Imaging Original Paper Owing to its pharmacodynamics and posology, the use of regadenoson for stress cardiac magnetic resonance (CMR) has potential advantages over other vasodilators. We sought to evaluate the safety, hemodynamic response and diagnostic performance of regadenoson stress-CMR in routine clinical practice. All regadenoson stress-CMR examinations performed between May 2017 and July 2020 at our institution were retrospectively reviewed. A total of 698 studies were included for the final analysis. A conventional stress/rest protocol was performed using a 1.5T MRI scanner (Magnetom Aera, Siemens Healthineers, Erlangen, Germany). Adverse events, clinical symptoms, and hemodynamic response were assessed. Diagnostic accuracy of the test was evaluated in patients who underwent invasive coronary angiography. Nearly half of patients (48.5%) remained asymptomatic. Most common clinical symptoms included dyspnea (137, 19.6%), chest pain (116, 16.6%) and flushing (44, 6.3%). Two patients (0.28%) could not complete the examination due to severe hypotension or unbearable chest pain. Overall, an increase in heart rate (HR) response (36.2% [IQR: 22.5?50.9]) and a decrease in systolic and diastolic blood pressure (BP) (median systolic BP response of -5% [IQR: -11.5-0.6]; median diastolic BP response of -6.3 mmHg [IQR: -13.4-0]) was observed. Patients with symptoms induced by regadenoson showed higher HR response (40.3%, IQR: 26.4?56.1 vs. 32.4%, IQR: 19-45.6, p < 0.001), whereas a blunted HR response was observed in diabetic (29.6%, IQR: 18.4?42 p < 0.001), obese (31.7%, IQR: 20.7?46.2 p = 0.005) and patients aged 70 years or older (32.9%, IQR: 22.6?43.1 p < 0.001). Overall, regadenoson stress-CMR showed 95.65% (IQ 91.49?99.81) sensitivity, 54.84% (IQ 35.71?73.97) specificity, 86.99% (IQ 82.74?94.68) positive predictive value, and 77.27% (IQ 57.49?97.06) negative predictive value for detecting significant coronary stenosis as compared with invasive coronary angiography. Regadenoson is a well-tolerated vasodilator that can be safely employed for stress perfusion CMR, with high diagnostic performance. Springer Netherlands 2023-06-24 2023 /pmc/articles/PMC10520095/ /pubmed/37354385 http://dx.doi.org/10.1007/s10554-023-02877-z Text en © The Author(s) 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Paper
Muñiz-Sáenz-Diez, Javier
Ezponda, Ana
Caballeros, Meylin
de la Fuente, Ana
Gavira, Juan J.
Bastarrika, Gorka
Safety, feasibility, and hemodynamic response of regadenoson for stress perfusion CMR
title Safety, feasibility, and hemodynamic response of regadenoson for stress perfusion CMR
title_full Safety, feasibility, and hemodynamic response of regadenoson for stress perfusion CMR
title_fullStr Safety, feasibility, and hemodynamic response of regadenoson for stress perfusion CMR
title_full_unstemmed Safety, feasibility, and hemodynamic response of regadenoson for stress perfusion CMR
title_short Safety, feasibility, and hemodynamic response of regadenoson for stress perfusion CMR
title_sort safety, feasibility, and hemodynamic response of regadenoson for stress perfusion cmr
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10520095/
https://www.ncbi.nlm.nih.gov/pubmed/37354385
http://dx.doi.org/10.1007/s10554-023-02877-z
work_keys_str_mv AT munizsaenzdiezjavier safetyfeasibilityandhemodynamicresponseofregadenosonforstressperfusioncmr
AT ezpondaana safetyfeasibilityandhemodynamicresponseofregadenosonforstressperfusioncmr
AT caballerosmeylin safetyfeasibilityandhemodynamicresponseofregadenosonforstressperfusioncmr
AT delafuenteana safetyfeasibilityandhemodynamicresponseofregadenosonforstressperfusioncmr
AT gavirajuanj safetyfeasibilityandhemodynamicresponseofregadenosonforstressperfusioncmr
AT bastarrikagorka safetyfeasibilityandhemodynamicresponseofregadenosonforstressperfusioncmr